Table 1

Characteristics of patients with vulvar, cervical, ovarian, and endometrial cancer who were actively working at the time of diagnosis, reported to MarketScan, diagnosed between 2009 and 2017 and followed through 2018

CharacteristicsVulvar cancerCervical cancerOvarian cancerEndometrial cancer
EC (n=30)No EC (n=161)P*EC (n=194)No EC (n=747)P*EC (n=383)No EC (n=1456)P*EC (n=972)No EC (n=3503)P*
Age at diagnosis, n (%) 0.40.4<0.001<0.001
44 or less4 (13.3)25 (15.5)100 (51.5)426 (57.0)76 (19.8)388 (26.6)121 (12.4)473 (13.5)
45 to 496 (20.0)33 (20.5)31 (16.0)126 (16.9)59 (15.4)241 (16.6)103 (10.6)439 (12.5)
50 to 533 (10.0)38 (23.6)19 (9.8)66 (8.8)55 (14.4)255 (17.5)121 (12.4)619 (17.7)
54 to 578 (26.7)29 (18.0)19 (9.8)49 (6.6)78 (20.4)274 (18.8)250 (25.7)904 (25.8)
58 to 639 (30.0)36 (22.4)25 (12.9)80 (10.7)115 (30.0)298 (20.5)
Health insurance plan type, n (%) 0.40.6440.9<0.001
HMO5 (16.7)15 (9.3)24 (12.4)111 (14.9)64 (16.7)227 (15.6)131 (13.5)553 (15.8)
PPO16 (53.3)101 (62.7)106 (54.6)405 (54.2)208 (54.3)806 (55.4)508 (52.3)2008 (57.3)
Other†9 (30.0)45 (28.0)64 (33.0)231 (30.9)111 (29.0)423 (29.1)333 (34.3)942 (26.9)
Region, n (%) 0.0020.7<0.001<0.001
Northeast5 (16.7)23 (14.3)34 (17.5)112 (15.0)61 (15.9)254 (17.4)186 (19.1)615 (17.6)
North central16 (53.3)35 (21.7)45 (23.2)158 (21.2)71 (18.5)270 (18.5)274 (28.2)791 (22.6)
South6 (20.0)81 (50.3)79 (40.7)338 (45.2)140 (36.6)659 (45.3)299 (30.8)1454 (41.5)
West3 (10.0)22 (13.7)36 (18.6)138 (18.5)111 (29.0)271 (18.6)212 (21.8)639 (18.2)
Unknown0 (0.0)0 (0.0)0 (0.0)1 (0.1)0 (0.0)2 (0.1)1 (0.1)4 (0.1)
Charlson Comorbidity Index score, n (%) 0.6<0.0010.70.2
026 (86.7)144 (89.4)174 (89.7)717 (96.0)348 (90.9)1332 (91.5)806 (82.9)2965 (84.6)
1+4 (13.3)17 (10.6)20 (10.3)30 (4.0)35 (9.1)124 (8.5)166 (17.1)538 (15.4)
Metastatic status, n (%)‡ 0.90.003<0.0010
Non-metastatic27 (90.0)146 (90.7)150 (77.3)643 (86.1)178 (46.5)922 (63.3)853 (87.8)3188 (91.0)
Metastatic3 (10.0)15 (9.3)44 (22.7)104 (13.9)205 (53.5)534 (36.7)119 (12.2)315 (9.0)
Treatment group, n (%) 0.90.2<0.001<0.001
Surgery only26 (86.7)136 (84.5)111 (57.2)476 (63.7)99 (25.8)662 (45.5)755 (77.7)2904 (82.9)
Surgery with adjuvant treatment4 (13.3)24 (14.9)50 (25.8)154 (20.6)244 (63.7)708 (48.6)202 (20.8)550 (15.7)
Chemotherapy, radiation, or chemoradiation only0 (0.0)1 (0.6)33 (17.0)117 (15.7)40 (10.4)86 (5.9)15 (1.5)49 (1.4)
Adverse events, n (%) 0.20.40.040.7
None28 (93.3)127 (78.9)177 (91.2)659 (88.2)264 (68.9)1094 (75.1)814 (83.7)2972 (84.8)
12 (6.7)33 (20.5)14 (7.2)78 (10.4)106 (27.7)315 (21.6)140 (14.4)474 (13.5)
2+0 (0.0)1 (0.6)3 (1.5)10 (1.3)13 (3.4)47 (3.2)18 (1.9)57 (1.6)
Year of diagnosis, n (%) 0.50.80.0310.2
20094 (13.3)14 (8.7)14 (7.2)67 (9.0)22 (5.7)122 (8.4)90 (9.3)296 (8.4)
20103 (10.0)10 (6.2)14 (7.2)76 (10.2)33 (8.6)126 (8.7)80 (8.2)339 (9.7)
20110 (0.0)11 (6.8)15 (7.7)61 (8.2)35 (9.1)149 (10.2)101 (10.4)357 (10.2)
20125 (16.7)17 (10.6)20 (10.3)64 (8.6)30 (7.8)150 (10.3)92 (9.5)384 (11.0)
20131 (3.3)18 (11.2)17 (8.8)68 (9.1)32 (8.4)115 (7.9)96 (9.9)358 (10.2)
20142 (6.7)16 (9.9)17 (8.8)72 (9.6)18 (4.7)120 (8.2)81 (8.3)363 (10.4)
20155 (16.7)14 (8.7)33 (17.0)98 (13.1)41 (10.7)154 (10.6)126 (13.0)428 (12.2)
20164 (13.3)27 (16.8)35 (18.0)123 (16.5)87 (22.7)260 (17.9)165 (17.0)515 (14.7)
20176 (20.0)34 (21.1)29 (14.9)118 (15.8)85 (22.2)260 (17.9)141 (14.5)463 (13.2)
  • *P values were derived using the χ2 test or Fisher’s exact test when appropriate.

  • †Other health insurance plans include comprehensive, point-of-service, point-of-service with capitation, high-deductible, and exclusive-provider-organization health plans.

  • ‡Metastatic status was derived using ICD 9/ICD 10 codes.

  • EC, employment change; HMO, health maintenance organization; ICD 9/ICD 10, International Classification of Diseases 9th and 10th editions; PPO, preferred provider organization.